Campbell Neurosciences Spin Off of Therapeutic Solutions Reports Synergistic Reduction of Schizophrenia in Animal Models using Low Dose Naltrexone and T Regulatory Cell Stimulation
Therapeutic Solutions International (OTC Markets: TSOI) announced findings validating its patent application, demonstrating a synergy between low dose naltrexone and T regulatory cell stimulators. In experiments, low dose naltrexone combined with interleukin-2 effectively reduced schizophrenic-like behavior in an animal model. The company aims to file an IND with the FDA soon, highlighting the importance of immune-brain interactions and repositioning safe drugs. Leadership expressed enthusiasm about leveraging immune modulation for treating schizophrenia, emphasizing the potential for innovative therapies.
- Validates patent claims regarding low dose naltrexone and T regulatory cells.
- Demonstrates effective reduction of schizophrenic-like behavior in animal models.
- Plans to file an IND with the FDA, signaling progress in drug development.
- Highlights immune-brain interaction, suggesting innovative treatment pathways.
- None.
ELK CITY, Idaho, June 16, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported today new data validating claims in its previously filed patent application demonstrating potent synergy between low dose naltrexone and agents stimulating T regulatory cells.
In one set of experiments, interleukin-2, an FDA cleared cancer immunotherapy drug is combined with low dose naltrexone to potently reduce schizophrenic-like behavior in an animal model of the condition. Naltrexone is a medication approved by the Food and Drug Administration (FDA) to treat both opioid use disorder and alcohol use disorder as a medication-assisted treatment option. Studies also showed that low dose naltrexone synergizes with mesenchymal stem cells and myeloid suppressor cells, both cell types are capable of inducing the generation of T regulatory cells in vivo.
"Schizophrenia is a major cause of suicide and suicidal ideation for which no real treatments exist in patients that are refractory to electroconvulsive therapy," said Kalina O'Connor, President and CEO of Campbell Neurosciences. "We are actively working at refining our various approaches so that we may file an IND with the FDA in the near term."
"From a physician perspective, I am much more comfortable repositioning drugs that have already been demonstrated safe, as opposed to introducing novel and untested compositions of matter in patients," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "The rapid rate of new findings by the Company is based upon a mechanistic-first approach, in which Campbell Scientists first started identifying cellular activities associated with reduction of schizophrenia, and subsequently began testing novel means of modulating the relevant cellular activities."
"The interplay between the immune system and nervous system is fascinating. The fact that immune modulation is associated with reduction in schizophrenic activities strongly supports the notion of the immune-brain interplay," said Timothy Dixon, President and CEO of Therapeutic Solutions International. "In my mind it is not a coincidence that out of all the systems of the body, only the brain and the immune system have the ability to tell between what is "self" and what is "non-self" and also to have memory. We are very excited about the work at Campbell, which will not only teach us how to modulate the brain with the immune system, but also how to modulate the immune system using neurological based approaches. The potency of this is difficult to overstate....imagine if we can generate immune stimulation by administration of select neuropeptides in order to biologically mimic, and amplify, the placebo effect."
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/
View original content:SOURCE Therapeutic Solutions International
FAQ
What new data did Therapeutic Solutions International (TSOI) report?
How does low dose naltrexone affect schizophrenia according to TSOI?
What is the company's plan for the FDA regarding their research?
What role do T regulatory cells play in TSOI's research?
When was the announcement made by Therapeutic Solutions International (TSOI)?
